MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc. (PMCB)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Cash Flow Overview
Change in Cash
-$864,908
Unit: Dollar
Positive Cash Flow Breakdown
Change in fair value of investme...
Change in fair value of warrants...
Adjustment from accrued liabilit...
Others
Negative Cash Flow Breakdown
Net loss
Change in fair value of warrant ...
Change in fair value of derivati...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-07-31
2026-04-30
2026-01-31
2025-10-31
Net loss
-5,081,191
-4,393,443
746,860
-7,417,975
Gain on related party investment - qcls
-
0
0
2,089,000
Issuance costs series c preferred stock and warrants
-
0
0
1,234,553
Loss on issuance of series c preferred stock
-
0
0
215,000
Gain on re-fair value of warrants
0
0
0
0
Non-cash interest income
-
-137,500
300,000
-
Non-cash warrant liability
-
0
-
-
Intangible asset impairment
-
1,549,427
-
-
Stock issued for compensation - rsus
-
0
771,516
60,492
Adjustment from accrued liabilities to warrant liabilities
469,000
-
-
-938,000
Stock-based compensation - options
0
54,580
181,476
-
Unrealized loss on marketable equity securities
-154,548
-118,241
-128,939
-60,663
Change in fair value of warrant liability
-
3,589,000
1,895,865
-10,474,000
Change in fair value of warrant liabilities
4,221,000
-
-
-
Change in fair value of derivative liability
597,000
258,000
557,000
302,000
Change in fair value of convertible note receivable - femasys
0
0
0
392,000
Change in fair value of warrant asset femasys
-414,000
-426,000
-214,000
-726,000
Change in fair value of investment qcls
-5,550,000
-4,247,000
1,725,000
-5,210,000
Change in fair value of warrants - qcls
-3,181,000
-1,397,000
-1,200,000
1,218,000
Increase in prepaid expenses and other current assets
123,509
316,481
-344,483
264,967
Increase in accounts payable
119,433
-842,561
178,743
469,711
Decrease in accrued expenses
-177,175
77,175
-544,000
-75,000
Net cash and cash equivalents used in operating activities
-780,894
-1,392,562
-786,848
-979,523
Investment in preferred stock and warrants - qcls
-
0
3,000,000
-
Investment in preferred stock and warrants
-
-
-
3,000,000
Proceeds from investment note receivable
-
0
5,000,000
-
Net cash provided by (used in) investing activities
-
0
5,000,000
-3,000,000
Repurchase of common stock, net
-
0
401,625
0
Net proceeds from issuance of series c preferred stock
-
-86,419
0
6,268,866
Net proceeds from warrant exercise
-
0
1,046,760
-
Redemption of preferred stock
-
0
0
0
Accrued series c convertible preferred stock and dividends
-
-
-
61,250
Payment of series c convertible preferred stock dividends
83,399
83,399
162,606
-
Net cash and cash equivalents used in financing activities
-83,399
-169,818
543,779
6,207,616
Effect of currency rate exchange on cash and cash equivalents
-615
744
2,587
-381
Net decrease in cash and cash equivalents
-864,908
-1,561,636
4,759,518
2,227,712
Cash and cash equivalents at beginning of the period
18,603,899
15,406,017
15,406,017
15,172,163
Cash and cash equivalents at end of the period
17,738,991
18,603,899
20,165,535
15,406,017
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
PMCB Cash Flow Sankey Diagram
Sankey diagram visualizing PMCB cash flow for the period
Net decrease in cash
and cash...
-$864,908
(56.62%↑ Y/Y)
Change in fair value of
investment qcls
-$5,550,000
Change in fair value of
warrants - qcls
-$3,181,000
Adjustment from accrued
liabilities to warrant...
$469,000
(0.00%↑ Y/Y)
Change in fair value of
warrant asset femasys
-$414,000
(65.93%↑ Y/Y)
Unrealized loss on
marketable equity...
-$154,548
(-47.95%↓ Y/Y)
Increase in accounts
payable
$119,433
(80.95%↑ Y/Y)
Net cash and cash
equivalents used in...
-$780,894
(60.84%↑ Y/Y)
Net cash and cash
equivalents used in...
-$83,399
Effect of currency rate
exchange on cash and cash...
-$615
(-600.00%↓ Y/Y)
Canceled cashflow
$9,887,981
Net loss
-$5,081,191
(39.22%↑ Y/Y)
Payment of series c
convertible preferred stock...
$83,399
Change in fair value of
warrant liabilities
$4,221,000
(1637.04%↑ Y/Y)
Change in fair value of
derivative liability
$597,000
something is missing
-$469,000
Decrease in accrued
expenses
-$177,175
(82.40%↑ Y/Y)
Increase in prepaid
expenses and other...
$123,509
(756.45%↑ Y/Y)
Buy us a coffee